Combining a GSI and BCL-2 inhibitor to overcome melanoma's resistance to current treatments

Major limitations of current melanoma treatments are for instances of relapse and the lack of therapeutic options for BRAF wild-type patients who do not respond to immunotherapy. Many studies therefore focus on killing resistant subpopulations, such as Melanoma Initiating Cells (MICs) to prevent rel...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Mukherjee, Nabanita, Almeida, Adam, Partyka, Katie A., Lu, Yan, Schwan, Josianna V., Lambert, Karoline, Rogers, Madison, Robinson, William A, Robinson, Steven E, Applegate, Allison J, Amato, Carol M, Luo, Yuchun, Fujita, Mayumi, Norris, David A., Shellman, Yiqun G.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2016
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5356684/
https://ncbi.nlm.nih.gov/pubmed/27829238
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13141
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi